SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as it drops below the key one-dollar psychological threshold, fueling intense debate between community members who view the dip as an institutional accumulation opportunity and those who are increasingly disillusioned by the lack of utility and regulatory progress. Critics are highlighting the coin's historical price volatility and continued supply dilution, while loyal holders continue to focus on long-term adoption narratives and potential institutional breakthroughs.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is gaining significant market attention as strong institutional buying and building technical momentum fuel talk of a potential short squeeze. Investors are actively discussing the company's long-term commercial growth, upcoming pipeline data for lung cancer, and the potential for a strategic acquisition as the firm transitions toward sustainable revenue.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing significant volatility driven by market concerns over off-balance-sheet financing risks related to its AI vehicle and competitive pressures, though institutional investors remain focused on its strong fundamentals and long-term AI infrastructure growth. The community is actively debating the reliability of these negative reports, with many seeing the price pullback as an attractive accumulation opportunity ahead of upcoming earnings.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is trending as investors debate the potential of its Texas data center project and energy infrastructure strategy amid recent earnings volatility. The community is actively discussing the company's progress on construction permits and land acquisition, while weighing concerns over cash burn and the lack of a finalized tenant contract.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as the community rallies behind a major governance proposal to activate a fee switch and initiate a massive token burn, fueling optimism regarding long-term protocol revenue and deflationary pressure. Traders are heavily debating the potential for a sustained price breakout while monitoring institutional interest and the asset's relative strength against the broader market.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently drawing significant attention from investors as they weigh the stock's massive short interest and potential for an explosive move against concerns over institutional dilution and a lack of official earnings date confirmation. The community remains deeply divided, with bulls pointing to the company's expansion into the sovereign AI infrastructure market and upcoming deployment milestones, while skeptics emphasize persistent management credibility issues and the risks associated with convertible note structures.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve Cannabis Corp is trending as investors react to its landmark NYSE listing and share buyback authorization, while the broader cannabis community closely monitors the upcoming DEA administrative law judge hearings regarding Schedule III rescheduling. Market participants are actively debating the long-term potential of U.S. multi-state operators versus Canadian producers, with many focused on Trulieve's market position ahead of anticipated federal banking and regulatory reforms.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy market volatility as investors debate the impact of share dilution and the company's aggressive Bitcoin treasury strategy. While community sentiment remains polarized between long-term bulls betting on institutional adoption and bears anticipating further downside, the stock remains a focal point for day traders watching for potential breakouts driven by high-beta momentum and complex options activity.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is trending as investors monitor the upcoming mid-2026 Phase 3 readout for its retinal therapeutic candidate, DURAVYU, amid heavy institutional accumulation and intense short interest. The community is actively debating the stock's potential for a massive short squeeze while weighing competitive dynamics in the wet AMD market against the company's recent capital raise.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is trending as investors focus on its critical role in the defense and C-UAS supply chain, particularly through its BlackDiamond technology which serves as a strategic substitute for restricted Germanium. The community is actively discussing the stock's potential for a significant re-rating as it pivots to a Western-aligned manufacturing footprint and secures ongoing interest from major defense contractors and government initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?

KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 211 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). These data highlight the significant unmet needs...

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV...

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to...

Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to receive...

KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High  - Here's Why

KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year High - Still a Buy...

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...

KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright

HC Wainwright cut shares of KalVista Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research report on Friday...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

KALVKalVista Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest KALV News